Duffett Stephen, El Hajjaji Imane, Manlucu Jaimie, Yee Raymond
Heart Rhythm Program, Department of Medicine, Western University, PO Box 5339, 339 Windermere Road, London, Ontario N6A 5A5, Canada.
Heart Rhythm Program, Department of Medicine, Western University, PO Box 5339, 339 Windermere Road, London, Ontario N6A 5A5, Canada.
Card Electrophysiol Clin. 2018 Mar;10(1):119-125. doi: 10.1016/j.ccep.2017.11.012. Epub 2017 Dec 14.
Defibrillation testing (DFT) during implantable cardioverter-defibrillator (ICD) implantation is still considered standard of care in some, but in increasingly fewer centers. The goal is to ensure that the device system functions as intended by testing in the controlled laboratory setting. Although safe, complications can occur and DFT is associated with an increased procedural time and cost. DFT is useful in assessing device function when programming changes or patient characteristics raise concerns regarding ICD efficacy. DFT remains standard of practice following implantation of subcutaneous ICDs and other specific circumstances. Implanting physicians should remain familiar with the process of DFT and situations where it is useful for individual patients.
在植入式心脏复律除颤器(ICD)植入过程中进行除颤测试(DFT)在一些中心仍被视为标准治疗方法,但采用这种方法的中心越来越少。其目的是通过在可控的实验室环境中进行测试,确保设备系统按预期运行。尽管DFT是安全的,但仍可能出现并发症,且与手术时间延长和成本增加相关。当编程更改或患者特征引发对ICD疗效的担忧时,DFT有助于评估设备功能。在植入皮下ICD后及其他特定情况下,DFT仍是标准操作。植入医生应熟悉DFT的流程以及对个别患者有用的情况。